برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Talzenna (talazoparib) Capsules Date of Approval: October 16, 2018 Company: Pfizer Inc. Treatment for: Breast Cancer Talzenna (talazoparib) is an oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. https://t.me/ppdprogram

➡️Yutiq (fluocinolone acetonide) Intravitreal Implant Date of Approval: October 12, 2018 Company: EyePoint Pharmaceuticals, Inc. Treatment for: Non-Infectious Posterior Segment Uveitis Yutiq (fluocinolone acetonide) is a corticosteroid intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. https://t.me/ppdprogram

➡️Nuzyra (omadacycline) Tablets and Lyophilized Powder for Injection Date of Approval: October 2, 2018 Company: Paratek Pharmaceuticals, Inc. Treatment for: Skin and Structure Infection, Pneumonia Nuzyra (omadacycline) is an aminomethylcycline tetracycline antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) https://t.me/ppdprogram

➡️Seysara (sarecycline) Tablets Date of Approval: October 1, 2018 Company: Almirall, S.A. Treatment for: Acne Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. https://t.me/ppdprogram

➡️Arikayce (amikacin liposome) Inhalation Suspension Date of Approval: September 28, 2018 Company: Insmed, Inc. Treatment for: Mycobacterium Avium Complex (MAC) Lung Disease Arikayce (amikacin liposome inhalation suspension) is an aminoglycoside antibacterial indicated for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options. https://t.me/ppdprogram

➡️Lumoxiti (moxetumomab pasudotox-tdfk) Injection Date of Approval: September 13, 2018 Company: AstraZeneca and MedImmune Treatment for: Hairy Cell Leukemia Lumoxiti (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia. https://t.me/ppdprogram

➡️Jivi (antihemophilic factor [recombinant] PEGylated-aucl) Injection Date of Approval: August 30, 2018 Company: Bayer HealthCare LLC Treatment for: Hemophilia A Jivi (antihemophilic factor (recombinant), PEGylated-aucl) is a recombinant DNA-derived, Factor VIII concentrate indicated to treat and control bleeding in patients with hemophilia A. https://t.me/ppdprogram

➡️Xerava (eravacycline) Injection Date of Approval: August 27, 2018 Company: Tetraphase Pharmaceuticals, Inc. Treatment for: Complicated Intra-Abdominal Infections Xerava (eravacycline) is a fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections. https://t.me/ppdprogram

➡️Altreno (tretinoin) Lotion Date of Approval: August 23, 2018 Company: Ortho Dermatologics Treatment for: Acne Altreno (tretinoin) is a topical retinoid for the treatment of acne. https://t.me/ppdprogram

➡️Inveltys (loteprednol etabonate) Ophthalmic Suspension Date of Approval: August 22, 2018 Company: Kala Pharmaceuticals, Inc. Treatment for: Postoperative Ocular Inflammation Inveltys (loteprednol etabonate) is a nanoparticle ocular corticosteroid formulation for the treatment of post-operative ocular inflammation and pain. https://t.me/ppdprogram

➡️Mulpleta (lusutrombopag) Tablets Date of Approval: July 31, 2018 Company: Shionogi Inc. Treatment for: Thrombocytopenia Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure. https://t.me/ppdprogram

➡️Krintafel (tafenoquine) Tablets Date of Approval: July 20, 2018 Company: GlaxoSmithKline Treatment for: Malaria Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of relapse) of Plasmodium vivax malaria. https://t.me/ppdprogram

➡️Qbrexza (glycopyrronium) Cloth for Topical Use Date of Approval: June 28, 2018 Company: Dermira, Inc. Treatment for: Hyperhidrosis Qbrexza (glycopyrronium) is a topical anticholinergic contained in a single-use, pre-moistened, medicated cloth for the treatment of primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years of age and older. https://t.me/ppdprogram

➡️Zemdri (plazomicin) Injection Date of Approval: June 25, 2018 Company: Achaogen, Inc. Treatment for: Urinary Tract Infection Zemdri (plazomicin) is an aminoglycoside antibacterial for the treatment of complicated urinary tract infections. https://t.me/ppdprogram

➡️Nocdurna (desmopressin acetate) Sublingual Tablets Date of Approval: June 21, 2018 Company: Ferring Pharmaceuticals Inc. Treatment for: Nocturia Nocdurna (desmopressin acetate) is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults. https://t.me/ppdprogram

➡️Olumiant (baricitinib) Tablets Date of Approval: May 31, 2018 Company: Eli Lilly and Company and Incyte Corporation Treatment for: Rheumatoid Arthritis, COVID-19, Alopecia Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. https://t.me/ppdprogram

➡️Consensi (amlodipine and celecoxib) Tablets Date of Approval: May 31, 2018 Company: Kitov Pharma Ltd. Treatment for: High Blood Pressure, Osteoarthritis Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis. https://t.me/ppdprogram

➡️Palynziq (pegvaliase-pqpz) Injection Date of Approval: May 24, 2018 Company: BioMarin Pharmaceutical Inc. Treatment for: Phenylketonuria Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria. https://t.me/ppdprogram

➡️Lokelma (sodium zirconium cyclosilicate) for Oral Suspension Date of Approval: May 18, 2018 Company: AstraZeneca Treatment for: Hyperkalemia Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults. https://t.me/ppdprogram

➡️Lucemyra (lofexidine hydrochloride) Tablets Date of Approval: May 16, 2018 Company: US WorldMeds Treatment for: Opiate Withdrawal Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal. https://t.me/ppdprogram